Payment overview · 2025
General Payments
$397.58
18 reported records · 7 companies
Healthcare provider profile · identity verified
Jaime Luis Torres, MD
Allopathic & Osteopathic Physicians|Internal Medicine · INVERNESS, FL · NPI 1174592638
Verified facts
What the public records show
CMS Open Payments records show Jaime Luis Torres, MD received $397.58 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $103.91 | 26.1% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.25 | 22.2% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.89 | 19.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $67.93 | 17.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.01 | 5.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.03 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.56 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $397.58 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.25 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $88.25 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $67.93 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $67.93 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.23 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.55 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.62 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 105 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
39 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
105 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
205 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 470 | 146 |
| Levothyroxine Sodium | Levothyroxine Sodium | 361 | 95 |
| Montelukast Sodium | Montelukast Sodium | 358 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 302 | 92 |
| Gabapentin | Gabapentin | 289 | 90 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 73 |
| Methylprednisolone | Methylprednisolone | 256 | 182 |
| Lisinopril | Lisinopril | 255 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 245 | 79 |
| Losartan Potassium | Losartan Potassium | 244 | 76 |
| Metformin Hcl | Metformin Hcl | 211 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 205 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 68 |
| Omeprazole | Omeprazole | 198 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 182 | 61 |
| Tramadol Hcl | Tramadol Hcl | 182 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 178 | 62 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 177 | 72 |
| Duloxetine Hcl | Duloxetine Hcl | 161 | 56 |
| Trazodone Hcl | Trazodone Hcl | 144 | 54 |
| Simvastatin | Simvastatin | 142 | 40 |
| Meloxicam | Meloxicam | 132 | 45 |
| Allopurinol | Allopurinol | 130 | 35 |
| Glimepiride | Glimepiride | 126 | 38 |
| Azithromycin | Azithromycin | 115 | 97 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 26 |
| Ezetimibe | Ezetimibe | 110 | 40 |
| Januvia | Sitagliptin Phosphate | 110 | 29 |
| Farxiga | Dapagliflozin Propanediol | 105 | 26 |
| Alprazolam | Alprazolam | 104 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 95 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 29 |
| Topiramate | Topiramate | 92 | 33 |
| Famotidine | Famotidine | 91 | 31 |
| Temazepam | Temazepam | 90 | 18 |
| Carvedilol | Carvedilol | 77 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 24 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 36 |
| Potassium Chloride | Potassium Chloride | 72 | 25 |
| Sildenafil Citrate | Sildenafil Citrate | 71 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 39 |
| Donepezil Hcl | Donepezil Hcl | 67 | 15 |
| Pregabalin | Pregabalin | 67 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 64 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 22 |
| Furosemide | Furosemide | 64 | 24 |
| Mirtazapine | Mirtazapine | 62 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 17 |
| Ozempic | Semaglutide | 60 | 21 |
| Calcitriol | Calcitriol | 59 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | suppressed |
| Finasteride | Finasteride | 57 | 20 |
| Eliquis | Apixaban | 56 | 14 |
| Bumetanide | Bumetanide | 53 | 21 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Jardiance | Empagliflozin | 50 | 11 |
| Xarelto | Rivaroxaban | 49 | 15 |
| Atenolol | Atenolol | 43 | 15 |
| Celecoxib | Celecoxib | 43 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 17 |
| Glipizide | Glipizide | 42 | 15 |
| Lorazepam | Lorazepam | 42 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 18 |
| Spironolactone | Spironolactone | 40 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 40 | 12 |
| Ondansetron Odt | Ondansetron | 39 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Prolia | Denosumab | 39 | 23 |
| Baclofen | Baclofen | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 31 | 18 |
| Diazepam | Diazepam | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 31 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 30 | 27 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 28 | 17 |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 14 |
| Cilostazol | Cilostazol | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 18 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 13 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 23 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Mupirocin | Mupirocin | 21 | 15 |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Prednisone | Prednisone | 20 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 15 |
| Nitroglycerin | Nitroglycerin | 18 | 11 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 16 |
| Glyburide | Glyburide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Tadalafil | Tadalafil | 15 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 14 | 12 |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Klor-Con 10 | Potassium Chloride | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Adcirca | Tadalafil | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $397.58 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, ELIQUIS, FARXIGA, Korlym, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error